Biological processes in normal wound healing Biological processes in failed wound healing
It has long been known that dermal wounds may show The healing of wounds results from a number of temporally impaired healing in patients with peripheral arterial occlusco-ordinated processes that involve several events driven ive disease (PAOD), deep vein thrombosis (DVT), and by locally released mediators. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The first event is immedidiabetes. For example, wounds in diabetic patients heal ate and consists of the activation of the coagulation cascade very slowly or not at all when compared with wounds and the production of a blood clot. After several minutes, in nondiabetics. Despite intense investigation, the precise an acute inflammatory response ensues. Subsequently, molecular mechanisms associated with impaired healing in leukocytes clear the wound of debris and release growth this patient group are poorly understood. A number of factors to initiate the healing process. Then follows the laboratories have shown reductions in the levels of growth first stage of collagen repair involving deposition and the factors and their receptors. These include PDGF recepformation of granulation tissue which becomes a new and tors, 20 IGF-I and IGF-II, 21 keratinocyte growth factor temporary weak tissue. The third and final process is the (KGF), 22 TGFβ and IGF-I, 23 TGFβ 1,2,3 and receptors. 24 second phase of collagen repair resulting in extracellular Consistent with these findings, several groups have shown matrix remodeling, angiogenesis, and the reproduction of that the application of growth factors may induce the full strength tissue comparable to the original skin. Much acceleration of cutaneous wound healing in murine models of the normal healing process is driven by growth factors.
of diabetes. These studies are described later. In addition to their role in blood clot formation, platelets generate a number of growth factors that are found in wound fluid, including transforming growth factor α Healthcare burden for the treatment of (TGFα), platelet-derived growth factor (PDGF), epidermal chronic wounds growth factor (EGF), vascular endothelial growth factor (VEGF), transforming growth factor β (TGFβ), and insulinUlcers associated with pressure and arterial and venous like growth factor I (IGF-I). [12] [13] [14] [15] In the inflammatory diseases response, neutrophil migration is induced by PDGF, Dermal ulcers are a common complication and frequent interleukin 1α (IL1α), IL8, tumor necrosis factor α (TNFα), cause of hospital admission for many patients suffering granulocyte macrophage colony-stimulating factor with diabetes. In 1992, in the UK, 2% of the diabetic (GM-CSF), and granulocyte colony-stimulating factor population were documented as having ulcer history with (G-CSF). [16] [17] [18] [19] Thus, multiple growth factors and cytokines approximately 0.5% having active ulcers at any one time. 25 There is a marked increase in dermal ulcer prevalence play a major role in wound healing.
with increasing age, and the number of patients with active and debridement. Prevention of sepsis is encouraged by application of silver sulfadiazine. This treatment is usually venous ulcers is estimated to be 280,000 in the UK and 1,300,000 in the USA. In 1989, in the UK, figures suggested sufficient for first and second degree burns to heal. Third and fourth degree burns may need the attention of a plastic that nursing costs alone accounted for £180 million, 26 consuming over 2% of the overall healthcare resources. It surgeon who may employ skin grafting as required. As all burns should be monitored for at least 6 weeks for is predicted that there will be an increase in the incidence of venous ulcers of 6% per annum.
hypertrophic scarring, it is inevitable that a proportion of burns would benefit from therapies that may reduce the In the UK, the risk of diabetics developing an ulcer is 3.1% 27 (compared with 1.6% for having an acute myocardincidence of red, thick, raised, and often itchy or painful hypertrophic scars. An ideal therapy would not only proial infarction within the same patient group). Diabetic foot ulceration is frequently the cause of amputation, the rate mote the rapid healing process, but would act as an antiscarring therapy. In terms of healthcare burden, the of which is 15 times higher for those with diabetes than for those without, leading to a total of about 10% of cost is estimated to be in excess of $0.7 billion per annum in the USA. diabetic ulcer patients requiring amputation. Two predisposing features which contribute to the high incidence of amputation are neuropathy and ischemia, both of which
UK and European treatment regimes
In the UK and in Europe, the vast majority of patients can lead to localized tissue trauma and subsequent tissue breakdown with necrosis and infection. In addition to with pressure sores or venous or arterial ulcers receive a treatment regime from their physician which comprises diabetes mellitus, several disease conditions may lead to impaired wound healing. These include venous insufficiency eschar debridement, antibiotic treatment where appropriate, and regular dressing. In the UK, there is little and cerebrovascular incidents. Many of these conditions have a high incidence in elderly patients. In Europe, the prospect for further treatment other than referral for skin grafting, which is only applicable when the wound bed is overall prevalence of patients with leg and foot ulceration is between 0.15 and 0.3%. In the Netherlands, diabetic well vascularized. For both venous and arterial ulcers, extensive tissue debridement, provision of a nonweightfoot ulceration caused hospitalization of 3707 patients in 1988 at a cost of Dfl.96 million. The incidence of arterial bearing regime, administration of antibiotics if infection is present, and regular changes of moist saline dressings diabetic ulcers is 2,350,000 in the USA and 170,000 in the UK. The cost of treatment per year is estimated at $16-21 constitute good ulcer care. Other dressings, such as hydrogels, hydrocolloids, or alginates, may also be used. billion in the USA 28 and $3-4 billion in the UK, and the costs of amputation are $1.5 billion in the USA and $30
Venous ulceration is treated by compression therapy (utilizing bandages which provide a graded compression from million in the UK. Again as a consequence of an enlarging elderly population, the market is set to increase at a rate heel to knee), whereas arterial or diabetic ulcers require regular changes of disinfected dressings. Pressure sores, of 14% per annum. 28 Pressure sores are described as localized areas of tissue once disinfected if necessary, are encouraged to heal by the relief of pressure at the injury site. This is achieved, for damage resulting from direct pressure on the skin (causing ischemia), or from shearing forces and friction (causing example, by the construction of padded surgical boots for pressure relief on the affected foot. mechanical stresses to the skin). The prevalence amongst hospital patients in the UK and USA is 7-8% and, as with venous stasis leg ulcers, the prevalence increases with age.
US treatment regimes
In addition to the standard healthcare provided in the UK The incidence in the USA is 2,900,000. The estimated costs of care for pressure sores are £150 million per annum in and the rest of Europe, patients in the USA may demand additional or alternative treatments. Some alternative treatthe UK and $3 billion in the USA and the market is set to grow at 5% per annum. 28 ments comprise administration of growth factors to the wounded area, or physical warming of the wound by ''warm up'' therapy. Various devices exist for warming a
Burns
In Northern America, approximately 1% of the population wounded area. The concept is that a wound does not have the ability to maintain a temperature of 37°C as a result (2.5 million people) are seen by a physician each year for a burn-related injury. 29 In 1964, the mortality associated of tissue loss. The wound warming device restores the wound to 37°C to provide the opportunity for healing by, with a 50% body burn was in excess of 50% of people, whereas in 1984 this figure was reduced to less than in part, increasing localized blood flow. Growth factor treatment includes the use of Regranex 10%. This accomplishment is due to the establishment of specialist burn centres. Good burn care includes rapid and (recombinant human PDGF B; reviewed later) and a cocktail of growth factors produced from a platelet releasate. sustained cooling of the affected area with water, cleansing, Although not as yet prescribed by the majority of centers for venous ulcers [30] [31] [32] to laser treatment, 33, 34 hyperbaric oxygen, 35, 36 and electrical stimulation for the treatment of in Europe, the use of growth factors may become more widespread if the current cost and hence burden to arterial ulcers. One particular regime of electrical stimulation that has achieved some success is the use of Dermahealthcare services can be reduced. pulse, 37,38 which we will review at length. For about 60 years it has been presumed that the Current therapies to promote healing application of low-dose direct current could have a positive effect on wound healing. This was demonstrated in numer-
Tissue engineered skin
Tissue engineering offers the possibility of creating physioous animal studies and in tissue culture. 39 In 1991, application of pulsed direct current achieved a reduction in the logically compatible human skin. With reference to wound care, the trend is to test artificial skin substitutes on burn wound area to under 45% of the original area for patients with skin ulcers of different etiologies after 4 weeks of wounds first and then progress to chronic wounds. The principal goal behind the use of a skin substitute is to treatment. In the control group, 67% of the wound area remained. 40 Since then different groups of investigators prevent bacterial infection and allow the wound the chance to heal by normal reparative processes. For all applications have documented the specific treatment of burns, 41 pressure necrosis, diabetic foot syndrome, keloids, and skin infecof tissue engineered skin, it is paramount that any preexisting infection has been cleared by the use of antibiotics tions with direct current. In 1983, it was postulated that tissue layers deeper than such as Penbritin or Floxapen. Some skin substitutes, e.g. Dermagraft (Advanced Tissue Sciences/Smith & Nephew), the skin have a negative potential as compared to the skin. This allows the skin wound to become charged by a positive are designed to replace the dermis and to provide essential stimulatory growth factors. In addition to Dermagraft potential. 42 The negative battery potential arises through the sodium ion pump. Throughout the wound the distribubeing approved for full thickness diabetic foot ulcers under a Food and Drug Administration (FDA) investigational tion of charge in the skin is disturbed. During wound healing, the flow of current is measurable, but ceases during device exemption, Dermagraft TC is indicated for the treatment of burns. Apligraf (Organogenesis/Novartis), the end of the wound healing process or during the nonphysiologic conditions in a dry ulcer. This offers, in indicated for venous stasis ulcers, gained FDA approval in May 1998 and comprises both a dermal and epidermal part, an explanation for the fact that wounds in a moist environment heal better. Tissue cells, such as macrophages, layer. Further clinical trials for burn treatment are underway.
mast cells, or granulocytes, migrate along the path of a voltage gradient. Direct current attracts granulocytes Other dermal skin substitutes, which include Biobrane (Dow B Hickman) and Integra (Integra), have been tested towards the cathode and establishes them in relatively higher numbers in human wound exudate. In a variety of in burns victims, and Alloderm (LifeCell) has recently been launched in the USA for patients with third degree burns investigations, in animal models as well as in humans, the improvement in the blood flow in the vicinity of the cathode and limited donor site tissue. Of the epidermal replacement products currently available, the most advanced comprises can be demonstrated. 43, 44 The Dermapulse instrument is a battery-powered medical cultured autologous epithelial cells grown to confluence in vitro. Epicel (Genzyme) is indicated for the treatment of device that delivers pulsed electrical stimulation. The instrument is powered by a 6-V lantern battery of the spring burns. Acticel, which is a nonautologous variation of Epicel, is in clinical trial as an active wound dressing for terminal type, which has a capacity of 20 A-h. The specifications of the instrument are described in Table 1 . patients with burns or ulcers.
It should be borne in mind that, unlike in burns patients, The device does not need calibration. There are external controls for the intensity, polarity, and frequency of the the condition in patients with chronic ulcers results from underlying diseases, which if effectively treated would current signals. The intensity and the remaining treatment time may be read from digital displays. The instrument reduce the use of skin replacement. Consequently, treatment of the underlying disease in addition to stimulation of the may be simultaneously connected to as many as four treatment electrodes and two dispersion electrodes. The wound healing process, either by physical stimuli or by the application of exogenous growth factors, may achieve a sterile treatment electrode is designed for single use and consists of a 10.7 ϫ 10.7 cm carbon-filled silicone rubber greater incidence of healing.
sheet which has a high conductivity. The nonwoven fabric covering and the polyester, saline-filled gauze pad have
Physical devices
Numerous physical devices have been employed in an antiadhesive characteristics. The dispersion electrode has a surface area of 1.3 ϫ 17.8 cm and is made from silver ink attempt to promote the healing of wounds. These range from compression bandages as the standard treatment applied to carbon-filled vinyl. A hydrogel adhesive serves 43.5% (P Ͻ 0.039). The oxygen level in the skin at the ulcer margin improved by 80%. The inflammatory erythema in the ulcer, as registered by the laser Doppler flux, decreased negligibly. In this study, it has been demonstrated that therapy resistant venous leg ulcers can be reduced in size or healed in a short period of time. The positive experiences of the electrostimulation of venous ulcers reported here will now stand the test of a prospective placebo-controlled study. The potential role of Dermapulse in the modulation of growth factor and receptor expression is currently under investigation. 45 Figure 1 Patients presenting with therapy resistant ulcers There have been many excellent reviews published on associated with chronic venous insufficiency were treated with growth factors as applied to the healing of wounds, 1,14,46-50
Growth factors
Dermapulse. The duration of the disease and the changes in and it is not our intention simply to add to the collection ulcer size were monitored throughout the treatment period with another general review. Neither is it possible in this review to describe the vast amount of literature that supports the role of growth factors in re-epithelialization, TGFβ was dependent upon the formulation of the topical delivery system. 54 Likewise PDGF B has been reported to promote re-epithelialization and revascularization in ischemic tissue and diabetic animals. 55, 56 The effect of as the skin contact medium. This electrode is usable for at least a week by a single patient.
PDGF is to significantly induce the ingrowth of repair tissue in wounds by upregulating granulation tissue formaIn one study, 37 patients with chronic venous insufficiency, who had suffered for years with therapy resistant ulcers, tion 55 and collagen gene expression. 57 In addition to a role for the promotion of healing within wounds, PDGF B has were treated with low-frequency pulsed current. The patients generally found the treatment to be pleasant. For recently been demonstrated to be effective for healing of the patellar ligament in a rat model of ligament injury, 58 the majority of the treated patients, there was a reduction in wound pain during the first few days, which substantially and PDGF and nerve growth factor (NGF) have been shown to be effective for repair of nerve damage in a rat increased the acceptance of the electrostimulation therapy. During therapy, the cutaneous microcirculation and the model of spinal cord injury. 59 These observations suggest that growth factors may have a general role for the ulcer size were closely investigated. As shown in Fig. 1 , some patients reached a reduction to 36.5% (P Ͻ 0.01) of improvement of soft tissue repair. Heparin binding epidermal growth factor-like growth the original ulcer area during an average treatment period of 38 days. The nutritive cutaneous perfusion was improved factor (HB-EGF) has been shown to accelerate healing of partial thickness burn wounds in murine models of burn in all of the ulcers. The immediate vicinity of the wound and the ulcer itself were investigated with the capillary injury when topically supplied via slow release cholesterollecithin pellets. In this study, the application of HB-EGF was microscope in order to document the morphologic characteristics and the increase in capillary density. In the study, associated with an increase in keratinocyte proliferation and production of endogenous TGFα. 60 the capillary density in the ulcer significantly improved by Measurement of growth factors in rodent models of and pressure ulcers. Of the 29,683 patients treated with streptozotocin-induced diabetes or genetically diabetic topically applied growth factors between 1988 and 1995, rodents has shown a reduction or a delay in expression of 78% of patients who presented with dermal ulcers and a number of growth factors, in particular acidic fibroblast who completed the program were healed. 5,10 growth factor (aFGF), basic fibroblast growth factor Regranex (Johnson & Johnson) is indicated for the (bFGF), TGFβ-like growth factors, PDGF B, and treatment of diabetic neuropathic ulcers. It is supplied as IGF-I. 22, 23, [61] [62] [63] [64] This had led to the use of platelet releasates a gel formulation for topical administration and PDGF B which contain a cocktail of growth factors that have been is its active biological. Supplied at either 0.003% or 0.01% shown to increase skin healing in animal models 62 and, PDGF B, Regranex has been studied in four clinical trials. 81 more importantly, in humans. As provided by Curative Of a total of 922 patients, 478 received Regranex at either Technologies Inc., Procuren, an autologous platelet releas-0.003% or 0.01% doses. Patients were randomized to ate, contains at least five growth factors that aid in the receive either good ulcer care alone or Regranex. In studies formation of granulation tissue and re-epithelialization. 5 1 and 2, the incidence of complete ulcer healing was The growth factors, which are PDGF, platelet-derived significantly greater in patients receiving Regranex comactivating factor (PDAF), platelet-derived epithelial growth pared with a placebo gel. In study 3, Regranex promoted factor (PDEGF), TGFβ, and platelet factor 4 (PF-4), have approximately a two-fold increase in the number of ulcers all been shown to aid wound repair. This autologous healed over a 20-week trial period. The fourth study, a growth factor mix, while not requiring FDA approval, has multicenter, evaluator blind study, showed no significant achieved some success in human subjects with ulcerated difference. Although these trial results show some promise, limbs. [65] [66] [67] These results in humans are supported by there is clear room for improvement, and it is tempting to earlier studies in animal models whereby growth factor speculate that the administration of two or more growth combinations were shown to synergistically activate healing factors may further increase the number and rate of in partial thickness porcine wounds 68,69 and in a genetically ulcers healed. diabetic mouse. 70 Nevertheless, this increased rate of healing obtained both in animal models and humans with multiple growth factors is indicative of the requirement of Clinical trials not a single growth factor but a complex mix of cell Despite the vast interest in growth factor and cytokine proliferative agents. Other growth factors that may accelerbiology and their potential for wound healing, clinical ate wound healing are EGF and bFGF. In a guinea pig skin trials have in most cases been disappointing. Topically excision model, both EGF and bFGF increased the thickness applied bFGF has shown some efficacy in the treatment of of the neodermis, 49 and PDGF, 71 bFGF, 72 NGF, 73 and chronic pressure sores, 82 and TGFβ for the treatment of aFGF 74 were able to reverse the healing impairment in venous stasis ulcers. 83 Some attempts at treatment have, protein-malnourished diabetic mice. Similarly, IGF-I was however, proved to be ineffective. In one study, EGF failed shown to accelerate healing in severely wounded senescent to heal venous stasis ulcers, 84 and in another IL-1 failed mice. 75 KGFs may also play a role in tissue repair. KGF to treat pressure sores effectively. 85 Equivocal results were (FGF-7) is a potent mitogen for keratinocytes, and applicareported with bFGF. 86 TGFβ 3 has been shown to accelerate tion of exogenous KGF caused a significant stimulation of healing without affecting the amount of scar formation. 87 the repair process, whereby re-epithelialization was More recently, despite encouraging results in animal models partially improved. [76] [77] [78] In addition, a polypeptide of less and entry into human clinical trials by Novartis, TGFβ 3 than 3 kDa from keratinocyte-conditioned medium 79 has was withdrawn from phase III trials in 1998 due to a lack been shown to stimulate cell proliferation. Finally, endothelof sufficient efficacy data. This highlights a dilemma that ial cell growth factor (ECGF), when delivered in a controlled plagues both academic researchers and their potential release formulation, has been shown to stimulate angiogencorporate sponsors alike: the relevance of animal models esis in rats, 80 and this may have important implications for wound studies. There is no chronic animal model of for wound healing.
ulceration and models of streptozotocin-induced diabetes do not develop ulcers. Given these shortcomings, it is in
Biologicals in the clinic
everbody's interest to temper results obtained with growth As of 1st January 1999, there are currently two biological factors and cytokines in acute models of wounding with therapeutics in the clinic. Procuren, as described previously, optimism and caution. A contributory factor to the discrepis an autologous mixture of naturally occurring growth ancies attained in efficacy between animal models and factors obtained from the alpha granules of the patient's humans may be ascribed to the levels of endogenous growth own platelets. Procuren is indicated for the treatment of chronic nonhealing ulcers, including diabetic, venous stasis, factors and cytokines. The levels of PDGF, bFGF, EGF, and TGFβ have been shown to vary widely in chronic ulosis. 93 In another study, delivery of TGFβ 1 cDNA was shown to enhance wound repair in rat skin. 94 Liposomewounds. 88 There are, however, some promising new clinical trials mediated transfer of tissues with FGF was demonstrated to increase the wound healing rate in diabetic rats. 95 underway and these will be summarized. PDGF AA and AB isoforms (Zymogenetics/Novo Nordisk/Johnson & Johnson) are in phase III trials for pressure ulcers. Phase
Delivery of therapeutic genes to the skin
The skin is an accessible barrier that represents a prime I/II trials have been completed for diabetic foot ulcers. Fibrostat (Procyon Biopharma), a growth factor antagonist site for gene delivery. 96 Such therapies may be directed against cutaneous conditions, e.g. psoriasis and dermal of collagen production, is in phase II/III trials for use following surgery and serious burns to reduce scarring.
wounds. As described above, DNA-coated particle bombardment by gene gun is one route into the skin. Other TGFβ 2 (Celtrix/Genzyme) is in phase II trials for both venous stasis and diabetic ulcers, and KGF-2 (Human direct physical ''injection'' techniques include the use of microseeding, 97 microfabricated needles, 98 and punctureGenome Sciences) is in phase II trials for burns, acute surgical wounds, and chronic wounds. EGF (Daewoong) mediated DNA transfer. 99 In addition, delivery of DNA complexed with lipids or liposomes 100,101 has been demonis in phase I/II trials for treatment of corneal and dermal wounds, and EGF (Johnson & Johnson/Ethicon/Chiron) is strated. Transport of macromolecules, as yet untested with DNA, has been achieved using depth-targeted pulsed in phase II trials for venous stasis ulcers and phase III trials for corneal repair after surgery. VEGF-2 (Vascular Genetics) electric fields 102 and ultrasound. 103 The development of gene-activated matrices (biodegradable polymers incorporis in phase I/II clinical trials for PAOD and has demonstrated angiogenesis and ulcer healing. Keratinocyte stimulating ating a therapeutic gene) takes the possibilities for wound treatment beyond gene therapy and into the realms of factors (Innogenetics) are in phase I/II trials for chronic ulcers and burns. Finally, Lyphoderm (Innogenetics), a tissue engineering. lyophilized epithelial lysate containing multiple growth factors, is in phase I trials for burns and the treatment of
Transcription factors (TFs) as therapeutic genes
TFs may have gene therapy applications for wound healing. chronic leg ulcers. Taken together, there is considerable optimism that one or more of these approaches may provide Hypoxia inducible factor-1 (HIF-1) is a basic helix-loophelix protein that activates the transcription of hypoxiaa better standard of treatment for many patients with nonhealing chronic ulcers.
inducible genes by binding to a hypoxic response element (HRE) in the gene promoter. 104 Genes that are regulated by HIF-1 include VEGF, erythropoietin, heme oxygenase-I, The potential for gene therapy inducible nitric oxide synthase, and the glycolytic enzymes aldolase A, enolase I, lactate dehydrogenase A, phosphoGene therapy to the skin, or to any other organ, is dependent on a number of factors. All gene delivery systems fructokinase I, and phosphoglycerate kinase I. HIF-1 exists in an active form as a heterodimer of HIF-1α and HIF-1β have the following aims. Firstly, they should be able to accept a suitable therapeutic gene and not be restricted by subunits. VEGF exists in a number of isoforms, and is hypoxia inducible. 105 Both VEGF-121 106 and VEGF-165 107 the size of the gene. Secondly, therapeutic genes need to be expressed at the correct level for the right amount of time.
isoforms, produced as splice variants of VEGF A, have been used in gene therapy, and VEGF B also has a role in Finally, the therapeutic gene must be in a delivery vehicle that is taken up by cells. The skin is an attractive target therapeutic angiogenesis. HIF-1 will activate the expression of all the VEGFs and, in theory, should elevate endogenous tissue for gene therapy, primarily because of its relative ease of accessibility, rendering an in vivo approach to gene VEGFs to a higher constitutive level than achieved under hypoxia, given that HIF-1 has been shown to superactivate delivery more feasible and allowing the monitoring of the genetically modified region. The molecular and cellular an HRE-containing promoter under hypoxic conditions. 108 The relative lack of promoter specificity may be an advantbiology of the epidermis has been very well characterized and a number of keratin gene promoters are available age as activation of other known HRE-dependent genes may not be deleterious. To date, studies have been confined which should, if required, target high-level tissue-specific expression in the epidermis. [89] [90] [91] to in vitro cell-based assays, where transient transfection of HIF-1α may activate expression of HRE-dependent Gene gun delivery of human EGF (hEGF) complementary DNA (cDNA) to a porcine wound model allowed healing genes. 109 The potential for HIF-1α to stimulate angiogenesis is being evaluated in animal models of hypoxia (Genzyme), 20% faster than controls. 92 In one study, gene gun delivery of TGFβ cDNA was compared with adenoviral delivery.
however, and a further application may include the treatment of ischemic ulcers. Provision of a TF gene payload TGFβ activity was restricted to the epidermis where it showed localized epidermal acanthosis and hypergranby topical delivery that will activate multiple members of the VEGF family of growth factors may induce revascularizReferences ation of the wounded area. 
